The transgenic and knock-out technologies have brought a new dimension into studies of gene function in vivo. It is now possible to insert new functional genes, and inactivate and modify the existing ones, in living organisms. We can for instance address the qualitative, quantitative and structure-function relations of genes and their regulatory sequences, and create animal models for genetic diseases in vivo. Other more practical applications of the transgenic technologies are the mass production of proteins and the genetic manipulation of farm animals and domestic plants. The current animal experiments with gene transfer will undoubtedly also pave the way to future gene therapy of human diseases. Reproductive biology has already begun to benefit from the novel transgenic techniques, which have helped elucidate the functions of the gonadotrophin genes, and findings in animals expressing other hormone genes have elucidated functions of the hypothalamicpituitary-gonadal axis. Although many intriguing studies in this field remain to be done, it is appropriate to summarize now the progress made in our understanding of gonadotrophin physiology and pathophysiology through transgenic animal studies.
Principles of the transgenic and knock-out techniques
With the transgenic techniques, genes or their fragments, isolated and modified in vitro, can be transferred as functional genes into living organisms, including mammals. Transgenic animals are produced by two common methods of gene transfer: DNA insertion by pronucleus injection or homologous recombination in embryonic stem cells (Figs 1 and 2 ). So far, pronucleus injection has been most widely applied for introducing new genetic material into a germline, and the most extensively studied transgenic animal species is the mouse, although other species have also been used (for example rat, rabbit, pig, carp, sheep, goat and cattle).
The pronucleus injection method (Box 1, Fig. 1 ), described in detail in laboratory manuals (for example Hogan et al., 1994) , has become the routine method in studies of overexpression and ectopic expression of genes in vivo, and for tracing specific promoter/enhancer functions (Table 1) . Usually, the resulting transgenic animals carry the transferred DNA in the genome of all their cells and, if cell-specific promoters are used, the expression of the transgene is strictly cell/tissue specific. Many factors influence the successful production of transgenic animals, including the species and strain of animal, the purity and form of DNA, and the practical skills of the investigator. Integration of the injected DNA into the genome of the host cell occurs relatively frequently, in random fashion, by a mechanism as yet unknown. The number of DNA copies integrated into the genome varies from one to several hundred, and this often plays an important role in the extent of transgene expression.
Gene targeting in embryonic stem cells (gene knock-out) provides a powerful tool for generating mice with designed mutations of endogenous genes in the germ line ( Fig. 2 ) (Capecchi, 1989; Bradley et al., 1992) . Embryonic stem cells are derived from the inner cell mass of blastocysts, grown on feeder cells, and transfected, for example by electroporation. This technology involves the disruption of specific endogenous genes of embryonic stem cells by introduced DNA via homologous recombination. The construct should contain, besides the homologous sequences of the gene of interest (viz. the mutated isogenic DNA), elements necessary for selection of the positive clones of embryonic stem cells. These are grown and selected in vitro and can contribute to all tissues, including the germ line, when fused with normal embryos and transferred into the uterus of pseudopregnant females. If the embryonic stem cells are fully competent, all the tissues of the resulting mice are chimaeric, and with further breeding it is possible to produce transgenic animals that carry the genomic modification in all their cells (Capecchi, 1989) . The possibility of producing other species of knock-out animals besides mice depends on the future availability of homologous embryonic stem cells. The gene targeting strategy allows one to answer questions via 'loss of function' experiments, as opposed to 'gain of function' experiments made possible by the pronucleus injection
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technique. Gene targeting can also be used to insert point mutations into the genome as a model for human genetic diseases. Moreover, since the transgene replaces a part of the native gene at its original site and thereby remains under the control of the cognate normal gene, these models more closely resemble genetic diseases caused by mutations.
The first successful experiments to induce tissue-specific ablation of a given endogenous gene, using the cre/lox technique, were reported by Gu et al. (1994) . In this technique, two 34 nucleotide lox (locus of recombination) sites are inserted by gene targeting (homologous recombination) into intronic sites of a desired gene, and an animal line is created. Another transgenic line is created by standard pronucleus injection, in which the bacteriophage P1 recombinase gene (cre) is expressed under a tissue-specific promoter. When the cre and lox mice are crossbred, some of the siblings express both transgenes, and the cre enzyme will cleave off, in tissue-specific fashion, the intervening DNA sequence between the two lox sites, thus resulting in tissue-specific disruption, and inactivation, of a desired gene. 
Studies of gonadotrophin subunit promoter function in transgenic mice
In one type of transgenic model, the gene constructs consist of a specific regulatory sequence (promoter) and a protein coding sequence used as reporter. This allows the identification in vivo of the critical promoter structures that determine the quantitative and tissue-specific expression. The 5'-flanking region of the common α-subunit gene has been most extensively studied (Table 2) . On the basis of the comparison between α-subunit promoters of several mammals, its function appears to have species-specific features, despite the relatively high conservation of these DNA sequences between many mammalian species (Gharib et al., 1990) . Kendall et al. (1994) showed that even 0.48 kilobases (kb) of the 5'-flanking sequence of the mouse common α-subunit gene can direct reporter gene expression to gonadotrophs and thyrotrophs of transgenic mice, while the human (1.6 and 1.8 kb) (Windle et al., 1990; Hamernik et al., 1992) and bovine (0.313 kb) (Kendall et al., 1991) α-subunit promoters confer the expression only to gonadotroph cells. Hormone replacement studies indicate that the 5'-flanking sequences of both human and bovine α-subunit/CAT transgenes respond to GnRH but not to propylthiouracil or T3 treatments (Hamernik et al., 1992) . Hence, the cell specificity of the α-subunit expression is regulated by distinct and separate regulatory elements. This is not surprising, given the differences in the endogenous α-subunit expression in the placentae of primates and horses, and its absence in other mammals (Fiddes and Talmadge, 1984) . There may also be species-specific differences in the regulation of the gonadotrophin β-subunit genes. Studies on transgenic mice demonstrate that in promoters of the human and mouse FSHβ genes, the essential DNA sequences for gonadotrophspecific expression are conserved, but those responsive to hormonal regulation differ (Kumar and Low, 1993) . The translation products of ovine LHβ (Brown et al., 1993) , bovine LHβ (Keri et al., 1994) , and bovine FSHβ (Markkula et al., 1995a) promoter-driven transgenes were found in the anterior pituitary only in part of the gonadotroph cell population. This may mean that the heterologous gonadotrophin subunit promoters do not function identically to the homologous promoter, or that the gonadotrophs are heterogeneous as regards their gonadotrophin subunit gene expression.
Transgenic animals harbouring specific promoter sequences are not only suitable for studying the physiology and tissuespecific functions of the genes but they can also reveal novel sites of expression of endogenous genes at various developmental stages. Kendall et al. (1994) showed that the endogenous α-subunit gene was expressed in embryonic extraocular and olfactory regions. These unexpected sites of expression were first suggested by findings on expression of a mouse α-subunit/ β-galactosidase gene in transgenic mice. The expression of the FSHβ promoter/herpes simplex virus thymidine kinase (HSV-tk) transgene in mouse ovary and testis prompted us to examine the gonadal expression of the endogenous gonadotrophin subunit genes. All were found to be expressed in specific cells of the ovary and testis (Markkula et al., 1995b; Zhang et al., 1995) . Figure 3 shows the localization of translation products of the FSHβ/HSV-tk transgene and endogenous FSHβ gene in the same mouse testicular cells.
Specific ablation of gonadotroph cells, and targeted disruption of gonadotrophin subunit genes
Specific cell ablation may be achieved by the pronucleus injection technique if the transgene contains a cell-specific promoter sequence and a toxic structural gene. The diphtheria toxin A-chain (DT-A) suicide gene (Kendall et al., 1991) and the inducibly toxic HSV-tk (Markkula et al., 1993 (Markkula et al., , 1995a , 1991) . The phenotype of these transgenic mice resembles closely the hypogonadal (hpg) mutant mouse (see below) with underdeveloped gonads and genitals, secondary to decreased LH and FSH secretion (Cattanach et al., 1977) . The gonadotroph ablation left the other pituitary cells intact, although gonadotrophs coexist and may interact with other cell types through gap junctions (Schwartz and Cherny, 1992) .
In practice, suicide toxigenes are not optimal for studying many aspects of reproduction since effective cell ablation of the transgenic mice most likely causes sterility. An alternative is to use the inducible toxicity of the HSV-tk gene. The HSV-tk toxigene is basically a neutral enzyme protein that does not affect the function of eukaryotic cells. However, it can convert certain nucleoside analogues (antiherpes drugs, such as gancyclovir or acyclovir) to toxic metabolites that kill dividing cells by arresting their DNA synthesis (Furman et al., 1980) . Induced ablation of gonadotrophs in transgenic mice harbouring 2.3 kb of the bovine FSHβ promoter, fused to the HSV-tk coding sequence, is pronounced in neonatal mice that have been treated in utero with acyclovir (given in drinking water to the pregnant animals), whereas in adult mice the gonadotrophs are more resistant to ablation treatment (Markkula et al., 1995a) . Although the inducibility of cell death with the thymidine kinase approach is a real asset of this technique, the mechanism of its action produces a considerable obstacle. Since dividing cells are most sensitive to induced ablation, the terminally differentiated cells (for example gonadotrophs) may be less sensitive to the cytotoxic effect. Kendall et al. (1995) have produced a mouse model with targeted disruption of the common α-subunit gene. These animals are totally devoid of the α/β heterodimers of LH, FSH and TSH, viz. the biologically active forms of these hormones. Consequently, the adult animals are severely hypothyroid and hypogonadal. This phenotype was expected, but intriguing new findings were made on the role of gonadotrophins in the perinatal sexual differentiation of the mice. In both sexes, fetal and neonatal differentiation of the genital structures was normal, indicating that the early endocrine activity of the gonads (especially fetal testicular testosterone production) occurs without influence of gonadotrophins. This is in keeping with the findings that the most active phase of testosterone production in the rodent fetal testis takes place in the presence of very low gonadotrophin production and probably without any LH stimulation (Huhtaniemi, 1994) . Other findings of this study included a marked decrease in the number of pituitary somatotroph and lactotroph cells, and an increase in the number of thyrotrophs. It will be interesting to find out about the phenotypes of mice with targeted disruption of the gonadotrophin β-subunit and gonadotrophin receptor genes.
Production of immortalized gonadotroph cell lines
Mellon and co-workers (Windle et al., 1990; Schechter et al., 1992) expressed the SV 40 virus T-antigen, a powerful viral oncogene, in transgenic mice under the common α-subunit promoter. The mice developed pituitary tumours, from which immortalized cell lines were derived. The cell lines retain the α-subunit expression, which responds to regulation by GnRH, but none of the glycoprotein β-subunit gene expression is maintained. Apparently the precursor cells that have not fully differentiated into gonadotrophs or thyrotrophs are transformed and arrested at an early stage of development. These cell lines are useful tools for a variety of studies in vitro on gonadotroph cell function, despite their loss of β-subunit expression. To our knowledge, immortalized gonadotrophs expressing the β-subunit genes have not yet been developed.
Gonadotrophin receptors
Transgenic mice expressing wild-type or mutant gonadotrophin receptor genes have not yet been produced. The only study on gonadotrophin receptor expression in transgenic mice so far published is that by Linder et al. (1994) , in which the chloramphenicol acetyl transferase (CAT) reporter gene (1991) was expressed under a 5 kb fragment of the 5'-flanking sequence of the rat FSH receptor gene. The transgene mRNA was detected by northern hybridization from a large amount of poly-A + RNA, but no translation product was found. The reason for the low expression was apparently the low activity of the FSH receptor promoter. Low activity of the LH receptor promoter has also been observed in expression of the mouse LH receptor/luciferase fusion gene in transgenic mice (M. Markkula and I. Huhtaniemi, unpublished). The FSH and LH receptor promoters would otherwise be ideal for targeting transgenes to specific gonadal somatic cells. There has been more success with a transgene targeting gonadal somatic cells using the inhibin α-subunit promoter (Kananen et al., 1995) . 
(a) (b)
Transgenic mouse models for diseases involving the function of gonadotrophins
A classic example of experimental germ line gene therapy for a disease involving reproductive endocrinology is the successful resumption of fertility in hpg mice: an animal model for hypogonadotrophic hypogonadism. These mice have a deletion in the GnRH gene (Mason et al., 1986a) , which is transcriptionally active but does not encode formation of functional GnRH protein. Consequently, the mice are hypogonadotrophic, sexually infantile and infertile (Cattanach et al., 1977) . Mason et al. (1986b) created transgenic hpg mice using a 13.5 kb fragment of mouse genomic DNA containing the GnRH gene. Transgenic hpg/hpg homozygotes of both sexes had normal pituitary and serum concentrations of gonadotrophins and prolactin, and were fertile. The transgene was expressed in the appropriate hypothalamic neurones of the transgenic hpg mice as a sign of their neural-specific expression. A normal pattern of GnRH expression during ontogeny was found to be critical for the restoration of fertility in the transgenic mice. This is apparently necessary for the GnRHdependent development of the neural connections needed for normal pulsatile GnRH secretion. If GnRH secretion of the hpg mice is restored by grafts of brain tissue to the preoptic area in adults, gonadotrophin secretion is restored but the female mice are in constant oestrus and exhibit reflux ovulation (Krieger et al., 1982; Gibson et al., 1984) . The males have no mating behaviour despite having testes of normal size (Krieger et al., 1982) . Hence, the lesson from the hypothalamic graft and transgenic experiments with the hpg mice is that the prenatal expression of GnRH is necessary for the proper development of the complex neural connections needed for normal hypothalamic-pituitary secretion of the reproductive hormones.
Another model for central hypogonadotrophic hypogonadism was created by expressing the SV40 virus T-antigen under the GnRH promoter (Windle et al., 1990) . During ontogeny, the expression of the viral oncogene apparently blocks normal migration of the GnRH neurones to the hypothalamus, thereby rendering the mice deficient in pulsatile GnRH secretion. Another gonadotrophin-deficient transgenic mouse model, closely resembling the hpg mice, has been created by expressing the DT-A gene under a 331 base pair fragment of the bovine α-subunit promoter (Kendall et al., 1991) .
Chronic hypersecretion of LH in transgenic mice provides a model for the pathogenesis of infertility, polycystic ovarian syndrome (PCOS) and ovarian tumours (Risma et al., 1995) . In this model, a chimaeric bovine LH β-subunit gene, either native, or containing the C-terminal extension of the hCG β-subunit, is expressed under the bovine common α-subunit promoter in transgenic mice. The transgene expression in females leads to a greater than tenfold increase in plasma LH concentrations in females, but not in males. The hCG C-terminus potentiates the phenotypic effects in the transgenic mice. Fertility is compromised in both sexes, more severely in females. Morphological analysis of ovaries reveals three types of pathology. (1) Enlargement and packed corpora lutea with prolonged lifespans and high progesterone production are observed. Thus hypersecretion of LH may overcome the physiological signals that normally trigger luteolysis. (2) Multiple ovarian cysts are found which, together with the increased androgen:oestrogen ratio, are reminiscent of human PCOS. Although the ovarian changes are not identical to human PCOS, this model may prove valuable in studies of this syndrome, which is known to have multifactorial pathogenesis. (3) Ovarian tumours of granulosa and theca-interstitial cell origin are seen, which provide novel evidence for a link between gonadotrophin secretion and ovarian tumourigenesis. This is of particular interest with respect to findings on the crystal structure of hCG, which suggest that gonadotrophins may belong to the superfamily of cystine-knot growth factors (nerve growth factor NGF; transforming growth factor β TGF-β; and platelet-derived growth factor β PDGF-β) (Lapthorn et al., 1994) . Additional abnormalities of the female transgenic mice overexpressing LH were enlarged bladders, dilated ureters and hydronephrosis. The chronically increased ovarian steroid production may contribute to these changes. No LH overproduction was found in the male mice, and only mild effects on their reproductive organs and functions were observed. The α-subunit promoter used may, therefore, be less tightly regulated by gonadal feedback in females. This study was thus unable to produce a male mouse model with persistently high LH concentrations, and other models are needed to address this question.
An FSH overexpressing transgenic model was developed by Kumar and co-workers (Kumar et al., 1992; Kumar and Low, 1993) , who expressed a 10 kb fragment of the human FSHβ genomic gene, including the cognate promoter sequences, in transgenic mice. The transgene was expressed in pituitary gonadotrophs and the protein product was secreted as human FSH β-subunit/mouse α-subunit interspecies heterodimers, resulting in increased concentrations of bioactive FSH. This did not change the fertility of either sex, but subtle changes, apparently due to the chronically increased FSH production, were found, including an increase of about 20% in size of the testes and an 80% increase in serum testosterone concentrations. These data are in keeping with the role of postnatal FSH secretion in determining the final testis size through regulation of Sertoli cell proliferation, and point to a possible FSHdependent paracrine factor of Sertoli cells stimulating Leydig cell function (Matikainen et al., 1994; Saez, 1994) .
Modulation of gonadotrophins by other transgene products
In addition to the studies addressing the function of gonadotrophin genes directly, there are several models in which the expression of other transgenes influences gonadotrophin secretion. Such studies can contribute valuable new information about the endocrine and paracrine interactions involved in gonadotroph functions. The GH overproducing mouse is one of the most extensively studied transgenic models (Hammer et al., 1985; Stewart, 1993; Bartke et al., 1994) . This model is complicated by the fact that the species of origin of the GH transgene determines whether the effects are pure GH effects or a combination of GH and prolactin effects, because human GH, but not bovine, ovine or rat GH, binds in rodents to both GH and prolactin receptors. Bartke and co-workers (for example, Bartke et al., 1994; Steger et al., 1994; Cecim et al., 1995) performed an extensive series of studies characterizing the reproductive functions of transgenic mice expressing various GH genes under powerful universal promoters (metallothionein-1 and phosphoenolpyruvate carboxykinase). The expression of the bovine GH gene (bGH; representing pure GH overproduction) leads, in both sexes, to reduced fertility, with the severity being related to the plasma concentrations of bGH. The bGH-expressing mice have accelerated sexual maturation, and increased number of ovulations and implantations, despite poor reproductive performance. In female mice, the infertility is often due to luteal failure. In the hypothalamic-pituitary-gonadal axis, the LH responses to various stimuli are inconsistent, but the FSH concentrations are suppressed owing to pre-and posttranslational effects.
The human GH-expressing male transgenic mice display additional endocrine effects due to combined increases in GH and prolactin activities (Posner et al., 1974) . Stimulation of LHβ mRNA expression and increased LH production occur apparently because of altered noradrenaline metabolism in the median eminence. The effects of the hGH transgenes are specific to LH, probably reflecting the increased lactogenic activity. In addition, the post-castration increases of LH and FSH are insensitive to reversal by testosterone. The hGH transgenic mice also display overstimulation of mammary glands, promotion of mammary tumourigenesis, and hypertrophy of accessory reproductive glands in males. Some of the hGH transgene effects on gonadotrophin secretion may also represent autocrine GH effects on gonadotrophs, since the metallothionein/hGH transgene is highly expressed in gonadotroph cells, owing to sequences in the 3'-flanking region of the hGH gene (Low et al., 1986a (Low et al., , 1989 . Taken together, high concentrations of GH exert a variety of direct and indirect, endo-, para-and autocrine effects on the hypothalamic-pituitarygonadal axis. The consequences of the prolonged GH, or GH and prolactin, effects are often quite different from the known physiological effects of these hormones, and may provide explanations for the variety of symptoms encountered in connection with hypersecretion of these hormones in humans.
The elegant series of gene knock-out studies by Matzuk and co-workers of genes of inhibin-α (Matzuk et al., 1992) , activin βA (Vassalli et al., 1994) , activin βB (Matzuk et al., 1995a) , activin receptor type II (Matzuk et al., 1995b) and follistatin (Matzuk et al., 1995c) shed light on the gonadal feedback regulation of gonadotrophin synthesis and secretion, in particular that of FSH. The inhibin-α knock-out mice develop normally at first, but later they acquire gonadal tumours and become infertile, apparently due to the tumours. The plasma FSH concentrations of the null mutant mice are clearly raised, in keeping with the important role of inhibin in the negative feedback regulation of FSH secretion. LH concentrations have not, so far, been measured in these animals. The activin βA and follistatin knock-out mice do not reveal much about the gonadotrophin regulation, since the animals die at birth as a result of craniofacial defects or failure to breathe. The female activin βB knockout mice display impaired fecundity with perinatal lethality of their offspring. Changes in FSH secretion are unlikely to be related to this since they are only about 20% greater than normal, and no pathological changes are apparent in the gonads. The activin type II receptor deficient mice develop normally to adulthood, have lowered FSH concentrations and their reproductive performance is deficient. However, the LH content of gonadotroph cells is normal. These findings demonstrate the crucial role of activin II receptor-mediated regulation of gonadotroph activity, and in particular that of FSH synthesis and secretion.
Other studies with transgenes unrelated to gonadotrophins have revealed responses of gonadotroph function. Altered neuroendocrine regulation of GnRH secretion and gonadal responses to gonadotrophin stimulation are found in transgenic mice overexpressing the transforming growth factor α (TGFα) gene under the metallothionein-1 promoter (Ma et al., 1994) , providing a model of influences of altered extrapituitary gene expression on gonadotrophin secretion. Unexpectedly, the metallothionein-somatostatin and metallothionein-human GH fusion genes were found to be highly expressed in gonadotroph cells (Low et al., 1986a,b) . The somatostatin peptide is secreted in the same fashion with LH and FSH from the gonadotrophs of the transgenic mice, but its possible autocrine effects on gonadotrophin production have not been investigated in further detail. Mice overexpressing the GH releasing hormone gene show no alterations of gonadotroph function, despite hyperplasia of mammosomatotroph cells (Stefaneanu et al., 1989) , indicating that there is no alteration in the paracrine interactions of these cell types. Studies with pituitary overexpression of various regulatory molecules are valuable in elucidating the auto-and paracrine mechanisms of gonadotrophin synthesis and secretion.
Future directions
Transgenic techniques have been applied with success to studies on the functions of the hypothalamic-pituitary-gonadal axis. However, only few clearly new concepts have been created, and, in many cases, the phenotypic changes have been so complicated that they have created more new questions than answers. The challenge for future research is to create better transgenic models. It is apparent that specific gene knock-out models are being developed for gonadotrophins and their receptors. These will be of great importance, as has already been demonstrated with the targeted disruption of the common α-subunit gene (Kendall et al., 1995) . There are several obvious studies that are likely to be carried out in the near future. Because the LH and FSH concentrations usually respond in concert to a variety of stimuli, there is still uncertainty about the specific individual roles of these two hormones. It would be extremely valuable to create animal models for single deficiency of LH or FSH. Such a knock-out model would provide the answer to a variety of questions, for example whether FSH production/action is an absolute requirement for normal testicular function. Crossbreeding of the single gonadotrophindeficient mice with transgenic strains developing pituitary or gonadal tumours would yield important information on the gonadotrophin dependence of such tumours. Likewise, overexpression or knock-out of gonadotrophin receptors would elucidate the gonadotrophin dependence of specific gonadal functions, and to what extent the paracrine mechanisms could compensate for missing gonadotrophin action. Several mutations and polymorphisms have been discovered in gonadotrophin and gonadotrophin receptor genes (see, for example, Shenker et al., 1993; Aittomäki et al., 1995; Kremer et al., 1995) . These result either in formation of hyperactive or inactive ligands, or in constitutively activated or inactivated forms of receptors. Transgenic models for such conditions would be useful for further studies of the pathophysiology of the above diseases, as well as for development of novel treatment strategies. The most interesting work with transgenic animals, concerning the physiology and pathophysiology of gonadotrophins, has yet to be carried out.
